New drug combo shows promise for Tough-to-Treat hodgkin lymphoma
NCT ID NCT02940301
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 24 times
Summary
This study tests a combination of two drugs, ibrutinib and nivolumab, in adults with classical Hodgkin lymphoma that returned or didn't respond to prior treatment. The goal is to see if the combination can shrink or eliminate cancer. About 18 participants will receive both drugs, and researchers will track how many achieve complete remission and how long the benefit lasts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Winship Cancer Center of Emory University
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.